By Catherine Eckford (European Pharmaceutical Review)2024-03-29T10:10:32
The long-acting injectable (LAI) formulation is indicated as a once-every-two-months treatment for adults with schizophrenia.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-30T10:47:00Z
Sponsored by CPhI
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, By European Pharmaceutical Review
2026-02-19T15:00:00 2026-02-19T16:00:00
Sponsored by Veolia
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
Site powered by Webvision Cloud